{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:19:40Z","timestamp":1779891580169,"version":"3.53.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T00:00:00Z","timestamp":1558396800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T00:00:00Z","timestamp":1558396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00198-019-05005-7","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T15:22:47Z","timestamp":1558538567000},"page":"1581-1589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis"],"prefix":"10.1007","volume":"30","author":[{"given":"W.","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2598-0346","authenticated-orcid":false,"given":"D.","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,21]]},"reference":[{"key":"5005_CR1","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726\u20131733","journal-title":"Osteoporos Int"},{"key":"5005_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2151458514520700","volume":"5","author":"D Godoy Monz\u00f3n","year":"2014","unstructured":"Godoy Monz\u00f3n D, Iserson KV, Jauregui J, Musso C, Piccaluga F, Buttaro M (2014) Total hip arthroplasty for hip fractures: 5-year follow-up of functional outcomes in the oldest independent old and very old patients. Geriatr Orthop Surg Rehabil 5:3\u20138","journal-title":"Geriatr Orthop Surg Rehabil"},{"key":"5005_CR3","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1359\/jbmr.2001.16.6.1056","volume":"16","author":"PK Venesmaa","year":"2001","unstructured":"Venesmaa PK, Kr\u00f6ger HP, Miettinen HJ, Jurvelin JS, Suomalainen OT, Alhava EM (2001) Monitoring of periprosthetic BMD after uncemented total hip arthroplasty with dual-energy X-ray absorptiometry \u2013 a 3-year follow-up study. J Bone Miner Res 16:1056\u20131061","journal-title":"J Bone Miner Res"},{"key":"5005_CR4","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1080\/17453670610013169","volume":"77","author":"HS Bod\u00e9n","year":"2006","unstructured":"Bod\u00e9n HS, Sk\u00f6ldenberg OG, Salemyr MO, Lundberg HJ, Adolphson PY (2006) Continuous bone loss around a tapered uncemented femoral stem: a long-term evaluation with DEXA. Acta Orthop 77:877\u2013885","journal-title":"Acta Orthop"},{"key":"5005_CR5","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1302\/0301-620X.83B4.11223","volume":"83","author":"O Furnes","year":"2001","unstructured":"Furnes O, Lie SA, Espehaug B, Vollset SE, Engesaeter LB, Havelin LI (2001) Hip disease and the prognosis of total hip replacements. A review of 53,698 primary total hip replacements reported to the Norwegian Arthroplasty Register 1987\u201399. J Bone Joint Surg (Br) 83:579\u2013586","journal-title":"J Bone Joint Surg (Br)"},{"key":"5005_CR6","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1359\/JBMR.050903","volume":"21","author":"ND Nguyen","year":"2006","unstructured":"Nguyen ND, Eisman JA, Nguyen TV (2006) Anti-hip fracture efficacy of biophosphonates: a Bayesian analysis of clinical trials. J Bone Miner Res 21:340\u2013349","journal-title":"J Bone Miner Res"},{"key":"5005_CR7","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.arth.2014.01.015","volume":"29","author":"AR Knusten","year":"2014","unstructured":"Knusten AR, Ebramzadeh E, Longjohn DB, Sangiorgio SN (2014) Systematic analysis of bisphosphonate intervention on periprosthetic BMD as a function of stem design. J Arthroplast 29:1292\u20131297","journal-title":"J Arthroplast"},{"key":"5005_CR8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/jor.20748","volume":"27","author":"M Arabmotlagh","year":"2009","unstructured":"Arabmotlagh M, Pilz M, Warzecha J, Rauschmann M (2009) Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty. J Orthop Res 27:183\u2013188","journal-title":"J Orthop Res"},{"key":"5005_CR9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.arth.2012.08.007","volume":"28","author":"DF Scott","year":"2013","unstructured":"Scott DF, Woltz JN, Smith RR (2013) Effect of zoledronic acid on reducing femoral bone mineral density loss following total hip arthroplasty: preliminary results of a prospective randomized trial. J Arthroplast 28:671\u2013675","journal-title":"J Arthroplast"},{"key":"5005_CR10","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1007\/s11999-015-4263-4","volume":"473","author":"M Khatod","year":"2015","unstructured":"Khatod M, Inacio MC, Dell RM, Bini SA, Paxton EW, Namba RS (2015) Association of bisphosphonate use and risk of revision after THA: outcomes from a US total joint replacement registry. Clin Orthop Relat Res 473:3412\u20133420","journal-title":"Clin Orthop Relat Res"},{"key":"5005_CR11","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/jbmr.2847","volume":"31","author":"KJ Bell","year":"2016","unstructured":"Bell KJ, Hayen A, Glasziou P, Irwig L, Eastell R, Harrison SL, Black DM, Bauer DC (2016) Potential usefulness of BMD and bone turnover monitoring of zoledronic acid therapy among women with osteoporosis: secondary analysis of randomized controlled trial data. J Bone Miner Res 31:1767\u20131773","journal-title":"J Bone Miner Res"},{"key":"5005_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3109\/17453674.2012.678798","volume":"83","author":"HT Aro","year":"2012","unstructured":"Aro HT, Alm JJ, Moritz N, M\u00e4kinen TJ, Lankinen P (2012) Low BMD affects initial stability and delays stem osseointegration in cementless total hip arthroplasty in women: a 2-year RSA study of 39 patients. Acta Orthop 83:107\u2013114","journal-title":"Acta Orthop"},{"key":"5005_CR13","first-page":"50","volume":"9","author":"M Muratore","year":"2012","unstructured":"Muratore M, Quarta E, Quarta L, Calcagnile F, Grimaldi A, Orgiani MA, Marsilio A, Rollo G (2012) Ibandronate and cementless total hip arthroplasty: densitometric measurement of periprosthetic bone mass and new therapeutic approach to the prevention of aseptic loosening. Clin Cases Miner Bone Metab 9:50\u201355","journal-title":"Clin Cases Miner Bone Metab"},{"key":"5005_CR14","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s00198-011-1797-5","volume":"23","author":"T Lin","year":"2012","unstructured":"Lin T, Yan SG, Cai XZ, Ying ZM (2012) Bisphosphonates for periprosthetic bone loss after joint arthroplasty: a meta-analysis of 14 randomized controlled trials. Osteoporos Int 23:1823\u20131834","journal-title":"Osteoporos Int"},{"key":"5005_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13018-015-0206-8","volume":"10","author":"X Zhao","year":"2015","unstructured":"Zhao X, Hu D, Qin J, Mohanan R, Chen L (2015) Effect of bisphosphonates in preventing femoral periprosthetic bone resorption after primary cementless total hip arthroplasty: a meta-analysis. J Orthop Surg Res 10:65","journal-title":"J Orthop Surg Res"},{"key":"5005_CR16","first-page":"1381","volume":"29","author":"M Chao","year":"2013","unstructured":"Chao M, Hua Q, Yingfeng Z (2013) Study on the role of zoledronic acid in treatment of postmenopausal osteoporosis women. Pak J Med Sci 29:1381\u20131384","journal-title":"Pak J Med Sci"},{"key":"5005_CR17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","volume":"38","author":"GH Nancollas","year":"2006","unstructured":"Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH (2006) Novel insights into actions of bisphosphonates on bone: differences in interaction with hydroxyapatite. Bone 38:617\u2013627","journal-title":"Bone"},{"key":"5005_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.arth.2015.07.017","volume":"31","author":"N Kobayashi","year":"2016","unstructured":"Kobayashi N, Inaba Y, Uchiyama M, Ike H, Kubota S, Saito T (2016) Teriparatide versus alendronate for the preservation of bone mineral density after Total hip arthroplasty - a randomized controlled trial. J Arthroplast 31:333\u2013338","journal-title":"J Arthroplast"},{"key":"5005_CR19","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S8756-3282(03)00091-7","volume":"32","author":"LB Tank\u00f3","year":"2003","unstructured":"Tank\u00f3 LB, Mouritzen U, Lehmann HJ, Warming L, Moelgaard A, Christgau S, Qvist P, Baumann M, Wieczorek L, Hoyle N, Christiansen C (2003) Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens. Bone 32:687\u2013693","journal-title":"Bone"},{"key":"5005_CR20","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1056\/NEJM198108133050704","volume":"305","author":"DM Slovik","year":"1981","unstructured":"Slovik DM, Adams JS, Neer RM, Holick MF, Potts JT Jr (1981) Deficient production of 1,25-dihydroxyvitamin D in elderly osteoporotic patients. N Engl J Med 305:372\u2013374","journal-title":"N Engl J Med"},{"key":"5005_CR21","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1007\/s00198-011-1868-7","volume":"23","author":"AS Carmel","year":"2012","unstructured":"Carmel AS, Shieh A, Bang H, Bockman RS (2012) The 25(OH) D level needed to maintain a favorable bisphosphonate response is \u226533ng\/ml. Osteoporos Int 23:2479\u20132487","journal-title":"Osteoporos Int"},{"key":"5005_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1371\/journal.pone.0209268","volume":"13","author":"A Bjork","year":"2018","unstructured":"Bjork A, Mellstrom D, Ohlsson C, Karlsson M, Mallmin H, Johansson G, Ljunggren O, Kindmark A (2018) Haplotypes in the CYP2R1 gene are associated with levels of 25(OH) D and bone mineral density, but not with other markers of bone metabolism. PLoS One 13:12","journal-title":"PLoS One"},{"key":"5005_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1056\/NEJM199202063260601","volume":"326","author":"MW Tilyard","year":"1992","unstructured":"Tilyard MW, Spears GF, Thomson J, Dovey S (1992) Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326:357\u2013362","journal-title":"N Engl J Med"},{"key":"5005_CR24","doi-asserted-by":"publisher","first-page":"274","DOI":"10.2106\/JBJS.G.01193","volume":"91","author":"G Friedl","year":"2009","unstructured":"Friedl G, Radl R, Stihsen C, Rehak P, Aigner R, Windhager R (2009) The effect of a single infusion of zoledronic acid on early implant migration in total hip arthroplasty. A randomized, double-blind, controlled trial. J Bone Joint Surg Am 91:274\u2013281","journal-title":"J Bone Joint Surg Am"},{"key":"5005_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00774-006-0734-8","volume":"25","author":"M Nagae","year":"2007","unstructured":"Nagae M, Hiraga T, Yoneda T (2007) Acidic microenvironment created by osteoclasts causes bone pain associated with tumor colonization. J Bone Miner Metab 25:99\u2013104","journal-title":"J Bone Miner Metab"},{"key":"5005_CR26","doi-asserted-by":"publisher","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","volume":"144","author":"SB Woo","year":"2006","unstructured":"Woo SB, Hellstein JW, Kalmar JR (2006) Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753\u2013761","journal-title":"Ann Intern Med"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-05005-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-019-05005-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-05005-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T23:29:58Z","timestamp":1589930998000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-019-05005-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,21]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["5005"],"URL":"https:\/\/doi.org\/10.1007\/s00198-019-05005-7","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,21]]},"assertion":[{"value":"10 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}